Table 1.

Trials III–IV DFS and OS pairwise comparisons according to ER status (median follow-up of 25 years)

			Disease-Free Survival			Overall Survival
	N	HR	95%CI	P *	5-Yr DFS% ± SE	25-yr DFS% ± SE	HR	95%CI	P *
Trial III [p+T:Obs]
ER+
p+T	45	0.65	0.42 to 1.00	0.05	56± 7	15± 5	0.78	0.50 to 1.23	0.29
Obs	53				30± 6	7± 4
ER−
p+T	30	1.08	0.63 to 1.85	0.77	20± 7	17± 7	1.22	0.70 to 2.12	0.48
Obs	33				30± 8	11± 6
Trial III [CMFp+T:Obs]
ER+
CMFp+T	58	0.62	0.41 to 0.92	0.02	58± 7	10± 5	0.82	0.54 to 1.26	0.37
Obs	53				30± 6	7± 4
ER−
CMFp+T	19	0.49	0.25 to 0.97	0.04	63±11	35±11	0.68	0.34 to 1.38	0.29
Obs	33				30± 8	11± 6
Trial III [CMFp+T:p+T]
ER+
CMFp+T	58	0.96	0.63 to 1.47	0.85	58± 7	10± 5	1.07	0.67 to 1.69	0.78
P+T	45				56± 7	15± 5
ER−
CMFp+T	19	0.44	0.22 to 0.89	0.02	63± 11	35±11	0.55	0.27 to 1.13	0.11
P+T	30				20± 7	17± 7
Trial III–IV [p+T:Obs] *
ER+
p+T	104	0.64	0.48 to 0.86	0.003	52± 5	11± 3	0.72	0.53 to 0.98	0.04
Obs	100				35± 5	4± 2
ER−
p+T	51	1.18	0.78 to 1.79	0.44	22± 6	10± 4	1.30	0.84 to 2.01	0.23
Obs	50				30± 6	13± 5

^*stratified by Trial.

Abbreviations: p+T: low-dose prednisone and tamoxifen for one year; CMF: classical cyclophosphamide, methotrexate, 5-fluorouracil for one year; Obs: observation: no adjuvant systemic therapy; ER: estrogen receptor status, HR: hazard ratio, CI: confidence interval, DFS: disease-free survival, OS: overall survival, SE: standard error